2025
Improved detection of circulating tumor DNA in patients with leiomyosarcoma with fragment size restriction.
Ruzgar N, Klega K, Ricker C, Tanhaemami M, Shafer A, Reinke D, Siontis B, Schuetze S, Crompton B. Improved detection of circulating tumor DNA in patients with leiomyosarcoma with fragment size restriction. Journal Of Clinical Oncology 2025, 43: 3046-3046. DOI: 10.1200/jco.2025.43.16_suppl.3046.Peer-Reviewed Original ResearchCell-free DNADetection of ctDNADetection of circulating tumor DNACycles of chemotherapyShort fragmentsDetectable ctDNACtDNA detectionTumor DNAHealthy controlsWhole-genome sequencingCopy number alterationsDiagnosis of leiomyosarcomaCell-free DNA samplesLiquid biopsy assayFragments of cell-free DNASequence dataRestriction analysisCtDNA levelsLeiomyosarcoma samplesNon-tumor originAssociated with lower likelihoodDNA samplesPrognostic valueFragment lengthBiopsy assayUltrasensitive circulating tumor DNA (ctDNA) detection for prognostication in triple-negative breast cancer (TNBC) post-neoadjuvant chemotherapy (NAC).
Cabel L, Lamy C, Keough K, Abbott C, Pouget N, Pierga J, Sablin M, Flavius J, Bronzini T, Laas E, Darrigues L, Feron J, Fourchotte V, Bonneau C, Vincent-Salomon A, Boyle S, Chen R, Le Tourneau C, Bidard F. Ultrasensitive circulating tumor DNA (ctDNA) detection for prognostication in triple-negative breast cancer (TNBC) post-neoadjuvant chemotherapy (NAC). Journal Of Clinical Oncology 2025, 43: 552-552. DOI: 10.1200/jco.2025.43.16_suppl.552.Peer-Reviewed Original ResearchTriple-negative breast cancerPathological complete responsePost-NACCtDNA detectionFollow-upPlasma ctDNADistant metastasisDistant relapse-free intervalPathological complete response statusPatients treated with NACTriple-negative breast cancer patientsEarly-stage TNBC patientsPost-surgical follow-upCtDNA-negative patientsCtDNA-positive patientsPost-neoadjuvant chemotherapyResidual disease levelsStratify survival outcomesImmune checkpoint inhibitorsNon-relapsing patientsRelapse-free intervalAdjuvant treatment decisionsMedian Follow-UpTumor-specific variantsMultivariate Cox modelIdentifying the optimal post-surgical timing of molecular residual disease (MRD) detection in colorectal cancer (CRC) using an ultra-sensitive assay: Interim results from the VICTORI study.
Solar Vasconcelos J, Titmuss E, Navarro F, Abbott C, Chia B, Topham J, Ladua G, Krishnan T, Hegebarth D, Lim H, Gill K, Gill S, Brown C, Ghuman A, Meneghetti A, Renouf D, Schaeffer D, Chen R, Boyle S, Loree J. Identifying the optimal post-surgical timing of molecular residual disease (MRD) detection in colorectal cancer (CRC) using an ultra-sensitive assay: Interim results from the VICTORI study. Journal Of Clinical Oncology 2025, 43: 275-275. DOI: 10.1200/jco.2025.43.4_suppl.275.Peer-Reviewed Original ResearchMolecular residual diseaseColorectal cancerCtDNA detectionDetection of molecular residual diseaseWeek 8Week 4Resectable colorectal cancerYear of surgeryTime of surgerySingle nucleotide variantsYear Follow-UpPost-surgical timesNeoadjuvant therapyResidual diseaseCurative intentMRD assaysResidual cancerClinical relapseDisease recurrenceCtDNA concentrationRecurrent cancerClinical outcomesCfDNA concentrationFollow-upRecurrence
2024
Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma
Botta G, Abdelrahim M, Drengler R, Aushev V, Esmail A, Laliotis G, Brewer C, George G, Abbate S, Chandana S, Tejani M, Malla M, Bansal D, Rivero-Hinojosa S, Spickard E, McCormick N, Cecchini M, Lacy J, Fei N, Kasi P, Kasi A, Dayyani F, Hanna D, Sharma S, Malhotra M, Aleshin A, Liu M, Jurdi A. Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma. The Oncologist 2024, 29: 859-869. PMID: 39022993, PMCID: PMC11449101, DOI: 10.1093/oncolo/oyae155.Peer-Reviewed Original ResearchMolecular residual diseasePancreatic ductal adenocarcinomaPatient survival outcomesCtDNA detectionSurvival outcomesStage I–III pancreatic ductal adenocarcinomaAssociated with shorter DFSMedian follow-up timeFollow-up timeCtDNA levelsResidual diseaseShorter DFSPrognostic factorsPancreatic adenocarcinomaAssociated with patient survival outcomesDuctal adenocarcinomaRetrospective analysisDiagnosed patientsMultivariate analysisSurveillance periodPatientsPlasma samplesTumor informationWhole exomeSurveillance windowUltra-sensitive ctDNA mutation tracking to identify molecular residual disease and predict relapse in patients with early breast cancer.
Garcia-Murillas I, Cutts R, Abbott C, Boyle S, Pugh J, Chen R, Dunne K, Bunce C, Johnston S, Ring A, Russell S, Evans A, Skene A, Wheatley D, Smith I, Turner N. Ultra-sensitive ctDNA mutation tracking to identify molecular residual disease and predict relapse in patients with early breast cancer. Journal Of Clinical Oncology 2024, 42: 1010-1010. DOI: 10.1200/jco.2024.42.16_suppl.1010.Peer-Reviewed Original ResearchMolecular residual diseaseCirculating tumor DNAEarly breast cancerBreast cancer patientsFollow-upNeoadjuvant chemotherapyResidual diseaseClinical relapseCtDNA detectionClinical outcomesBreast cancerAssociated with relapse free survivalDetection of molecular residual diseaseCancer patientsCirculating tumor DNA levelsLevels of circulating tumor DNAHigh risk of relapseHigh riskCirculating tumor DNA detectionMedian lead-timeRelapse free survivalDe-escalation studiesBreast cancer relapseShortened overall survivalBaseline prior to treatmentMulti-Institutional Study Evaluating the Role of Circulating Tumor DNA in the Management of Appendiceal Cancers
Belmont E, Bansal V, Yousef M, Zeineddine M, Su D, Dhiman A, Liao C, Polite B, Eng O, Fournier K, White M, Turaga K, Shen J, Shergill A. Multi-Institutional Study Evaluating the Role of Circulating Tumor DNA in the Management of Appendiceal Cancers. JCO Precision Oncology 2024, 8: e2300531. PMID: 38723230, DOI: 10.1200/po.23.00531.Peer-Reviewed Original ResearchConceptsCirculating tumor DNAComplete cytoreductive surgeryCirculating tumor DNA detectionAppendiceal cancerPeritoneal metastasisGrade 2Systemic therapyTumor DNAComplete CRSAssociated with shorter recurrence-free survivalCirculating tumor DNA testingShorter recurrence-free survivalSystemic therapy responseRecurrence-free survivalDiagnosis of recurrenceDetection of recurrenceMulti-institutional studyCytoreductive surgerySystemic chemotherapyCA19-9Elevated biomarkersTherapy responseCtDNA detectionSpecialized centersCarcinoembryonic antigenUtility of Circulating Tumor DNA Assessment in Characterizing Recurrence Sites after Optimal Resection for Metastatic Colorectal Cancer.
Bansal V, Belmont E, Godley F, Dhiman A, Witmer H, Li S, Liao A, Eng O, Turaga K, Shergill A. Utility of Circulating Tumor DNA Assessment in Characterizing Recurrence Sites after Optimal Resection for Metastatic Colorectal Cancer. Journal Of The American College Of Surgeons 2024, 238: 1013-1020. PMID: 38299640, DOI: 10.1097/xcs.0000000000001028.Peer-Reviewed Original ResearchConceptsMetastatic colorectal cancerRecurrence siteOptimal resectionCtDNA detectionDistant recurrenceColorectal cancerClinical diagnosis of recurrenceDiagnosis of recurrenceDistant lymph nodesSingle-institution studyLevels of ctDNACtDNA assessmentCtDNA levelsDistant diseaseCtDNA testingPostoperative recurrenceRecurrent casesLymph nodesMonths postsurgeryDisease sitesResectionRecurrenceDNA assessmentPatientsCRC metastasis
2023
Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA
Abbosh C, Frankell A, Harrison T, Kisistok J, Garnett A, Johnson L, Veeriah S, Moreau M, Chesh A, Chaunzwa T, Weiss J, Schroeder M, Ward S, Grigoriadis K, Shahpurwalla A, Litchfield K, Puttick C, Biswas D, Karasaki T, Black J, Martínez-Ruiz C, Bakir M, Pich O, Watkins T, Lim E, Huebner A, Moore D, Godin-Heymann N, L’Hernault A, Bye H, Odell A, Kalavakur P, Gomes F, Patel A, Manzano E, Hiley C, Carey N, Riley J, Cook D, Hodgson D, Stetson D, Barrett J, Kortlever R, Evan G, Hackshaw A, Daber R, Shaw J, Aerts H, Licon A, Stahl J, Jamal-Hanjani M, Birkbak N, McGranahan N, Swanton C. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature 2023, 616: 553-562. PMID: 37055640, PMCID: PMC7614605, DOI: 10.1038/s41586-023-05776-4.Peer-Reviewed Original ResearchConceptsCirculating tumor DNANon-small-cell lung cancerMetastatic disseminationClinical outcomesPlasma samplesEarly-stage non-small-cell lung cancerCirculating tumor DNA levelsCirculating tumor DNA detectionCytotoxic adjuvant therapyPreoperative ctDNA detectionResidual tumor cellsLongitudinal plasma samplesCancer cell fractionBiomarker of relapseProcess of metastatic disseminationAnalysis of plasma samplesClinical relapseDisease relapseAdjuvant therapyTumor DNAPreoperative plasmaRadiological surveillanceCtDNA detectionPatient cohortTumor cells
2022
Circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor–positive, HER2-negative breast cancer (CHiRP).
Lipsyc-Sharf M, De Bruin E, Santos K, McEwen R, Stetson D, Patel A, Kirkner G, Hughes M, Tolaney S, Krop I, Knape C, Feger U, Marsico G, Howarth K, Winer E, Lin N, Parsons H. Circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor–positive, HER2-negative breast cancer (CHiRP). Journal Of Clinical Oncology 2022, 40: 103-103. DOI: 10.1200/jco.2022.40.16_suppl.103.Peer-Reviewed Original ResearchMinimal residual diseaseDistant metastatic recurrenceAdjuvant endocrine therapyWhole-exome sequencingEndocrine therapyMetastatic recurrenceClinical outcomesBreast cancerHormone receptor-positive breast cancerPlasma samplesTumor tissueHER2-negative breast cancerReceptor-positive breast cancerTumor DNACtDNA detectionRegular surveillance imagingStage 3 diseaseCurative intent chemotherapyTime of consentPrimary tumor tissuesCurrent practice standardsSufficient tumor tissueLiquid biopsy testsAdjuvant settingCtDNA dynamics
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply